Literature DB >> 11381569

Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Y Yano1, S L Beal, L B Sheiner.   

Abstract

The posterior predictive check (PPC) is a model evaluation tool. It assigns a value (pPPC) to the probability that the value of a given statistic computed from data arising under an analysis model is as or more extreme than the value computed from the real data themselves. If this probability is too small, the analysis model is regarded as invalid for the given statistic. Properties of the PPC for pharmacokinetic (PK) and pharmacodynamic (PD) model evaluation are examined herein for a particularly simple simulation setting: extensive sampling of a single individual's data arising from simple PK/PD and error models. To test the performance characteristics of the PPC, repeatedly, "real" data are simulated and for a variety of statistics, the PPC is applied to an analysis model, which may (null hypothesis) or may not (alternative hypothesis) be identical to the simulation model. Five models are used here: (PK1) mono-exponential with proportional error, (PK2) biexponential with proportional error, (PK2 epsilon) biexponential with additive error, (PD1) Emax model with additive error under the logit transform, and (PD2) sigmoid Emax model with additive error under the logit transform. Six simulation/analysis settings are studied. The first three, (PK1/PK1), (PK2/PK2), and (PD1/PD1) evaluate whether the PPC has appropriate type-I error level, whereas the second three (PK2/PK1), (PK2 epsilon/PK2), and (PD2/PD1) evaluate whether the PPC has adequate power. For a set of 100 data sets simulated/analyzed under each model pair according to a stipulated extensive sampling design, the pPPC is computed for a number of statistics in three different ways (each way uses a different approximation to the posterior distribution on the model parameters). We find that in general; (i) The PPC is conservative under the null in the sense that for many statistics, prob(pPPC < or = alpha) < alpha for small alpha. With respect to such statistics, this means that useful models will rarely be regarded incorrectly as invalid. A high correlation of a statistic with the parameter estimates obtained from the same data used to compute the statistic (a measure of statistical "sufficiency") tends to identify the most conservative statistics. (ii) Power is not very great, at least for the alternative models we tested, and it is especially poor with "statistics" that are in part a function of parameters as well as data. Although there is a tendency for nonsufficient statistics (as we have measured this) to have greater power, this is by no means an infallible diagnostic. (iii) No clear advantage for one or another method of approximating the posterior distribution on model parameters is found.

Entities:  

Mesh:

Year:  2001        PMID: 11381569     DOI: 10.1023/a:1011555016423

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  5 in total

1.  A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron.

Authors:  E H Cox; C Veyrat-Follet; S L Beal; E Fuseau; S Kenkare; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1999-12

Review 2.  Pharmacokinetic/pharmacodynamic modeling in drug development.

Authors:  L B Sheiner; J L Steimer
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

3.  A population pharmacokinetic model for docetaxel (Taxotere): model building and validation.

Authors:  R Bruno; N Vivier; J C Vergniol; S L De Phillips; G Montay; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1996-04

4.  The analysis of repeated-measures data on schizophrenic reaction times using mixture models.

Authors:  T R Belin; D B Rubin
Journal:  Stat Med       Date:  1995-04-30       Impact factor: 2.373

5.  A Markov mixed effect regression model for drug compliance.

Authors:  P Girard; T F Blaschke; H Kastrissios; L B Sheiner
Journal:  Stat Med       Date:  1998-10-30       Impact factor: 2.373

  5 in total
  181 in total

1.  Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.

Authors:  Ying Hong; Kenneth G Kowalski; Jenny Zhang; Li Zhu; Mariaarantxa Horga; Richard Bertz; Marc Pfister; Amit Roy
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.

Authors:  Manjunath P Pai; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

3.  A joint model for nonlinear longitudinal data with informative dropout.

Authors:  Chuanpu Hu; Mark E Sale
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-02       Impact factor: 2.745

4.  Automatic data binning for improved visual diagnosis of pharmacometric models.

Authors:  Marc Lavielle; Kevin Bleakley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-26       Impact factor: 2.745

5.  Evaluation of graphical diagnostics for assessing goodness of fit of logistic regression models.

Authors:  Venkata V Pavan Kumar; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

Review 6.  Implementation of a standardized pain management in a pediatric surgery unit.

Authors:  B Messerer; A Gutmann; A Weinberg; A Sandner-Kiesling
Journal:  Pediatr Surg Int       Date:  2010-07-13       Impact factor: 1.827

7.  Population pharmacokinetic analysis of carboxyhaemoglobin concentrations in adult cigarette smokers.

Authors:  Carol Cronenberger; Diane R Mould; Hans-Juergen Roethig; Mohamadi Sarkar
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

8.  Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients.

Authors:  Géraldine Pettersen; Mohamad-Samer Mouksassi; Yves Théorêt; Line Labbé; Christophe Faure; Bao Nguyen; Catherine Litalien
Journal:  Br J Clin Pharmacol       Date:  2008-10-23       Impact factor: 4.335

9.  Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir.

Authors:  Fenglei Huang; Kristin Drda; Thomas R MacGregor; Joseph Scherer; Lois Rowland; Thuy Nguyen; Charles Ballow; Mark Castles; Patrick Robinson
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

10.  Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux.

Authors:  D Groenendaal; J Freijer; D de Mik; M R Bouw; M Danhof; E C M de Lange
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.